References
- Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473.
- World Health Organization. Coronavirus disease 2019 (COVID-19). Situation Report–51; Accessed 01 February 2021 (https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf)
- Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar-Apr;34:101623.
- Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 2020;395(10229):1014–1015.
- Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020Jul1; 180(7)934–943. Erratum in: JAMA Intern Med. 2020 Jul 1;180(7):1031
- World Health Organization. Coronavirus disease 2019 (COVID-19). Weekly epidemiological update - 6-19 July 2021. Accessed 19 July 2021 (: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—6-july-2021)
- European Centre for Disease Prevention and Control. Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV. Accessed 22 February 2021 (https://www.ecdc.europa.eu/en/publications-data/guidelines-use-non-pharmaceutical-measures-delay-and-mitigate-impact-2019-ncov)
- Anderson RM, Heesterbeek H, Klinkenberg D, et al. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020;395(10228):931–934.
- Teslya A, Pham TM, Godijk NG, et al. Impact of self-imposed prevention measures and short-term government-imposed social distancing on mitigating and delaying a COVID-19 epidemic: a modelling study. PLoS Med. 2020Jul21; 17(7)e1003166. Erratum in: PLoS Med. 2020 Dec 4;17(12):e1003499
- Roper RL, Rehm KE. SARS vaccines: where are we? Expert Rev Vaccines. 2009 Jul;8(7):887–898.
- Nota informativa MUH AEMPS, 38/2020 La EMA recomienda la autorización de la primera vacuna frente a la COVID-19. 2020 Accesed 01 February 2021 (https://www.aemps.gob.es/informa/notasinformativas/laaemps/2020-laaemps/la-ema-recomienda-la-autorizacion-de-la-primera-vacuna-frente-a-la-covid-19/)
- Nota informativa MUH AEMPS, 1/2021: la EMA recomienda la autorización de la segunda vacuna frente a la COVID-19. Accessed 01 February 2021. https://www.aemps.gob.es/informa/notasinformativas/laaemps/2021-2/la-ema-recomienda-la-autorizacion-de-la-segunda-vacuna-frente-a-la-covid-19/
- European Medicines Agency. Spikevax (previously COVID-19 vaccine Moderna): summary of product characteristics. 2021 Accessed 02 February 2021 (https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf).
- European Medicines Agency. Comirnaty: summary of product characteristics. Accessed 02 February 2021 (https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf).
- Wise J. Covid-19: people who have had infection might only need one dose of mRNA vaccine. BMJ. 2021 Feb 2;372:n308.
- Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021 Apr 8;384(14):1372–1374.
- Meo SA, Bukhari IA, Akram J, et al. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663–1669.
- Guidance for Industry. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. FDA, Sept 2007. https://www.fda.gov/media/73679/download; 2021 [cited 2021 Feb 7].
- Baden LR, El Sahly HM, Essink B, et al., Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 384(5): 403–416. 2021.
- Polack FP, Thomas SJ, Kitchin N, et al., Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 383(27): 2603–2615. 2020.
- 7º Informe de Farmacovigilancia sobre Vacunas Covid-19. https://www.aemps.gob.es/informa/boletines-aemps/boletin-fv/2021-boletin-fv/7o-informe-de-farmacovigilancia-sobre-vacunas-covid-19/; 2021 [cited 2021 Jul 27].
- Riad A, Pokorná A, Attia S, et al. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7):1428.
- Klugar M, Riad A, Mekhemar M, et al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers. Biology (Basel). 2021;10(8):752.
- Riad A, Hocková B, Kantorová L, et al. Side effects of mRNA-based COVID-19 vaccine: nationwide Phase IV study among healthcare workers in Slovakia. Pharmaceuticals. 2021;14(9):873.